Afuco™ Anti-Human CLDN18 ADCC Therapeutic Antibody (claudiximab), ADCC Enhanced
Anti-CLDN18 ADCC Enhanced Antibody (claudiximab) is an ADCC enhanced antibody produced by our Afuco™ platform. Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects).
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-158CL |
| Pricing | Inquiry |
| Host | Chimeric undefined source |
| Target | CLDN18 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at -20°C. Avoid multiple freeze/thaw cycles. |